Signaling by Ligand-Responsive EGFR Variants in Cancer

Stable Identifier
R-HSA-5637815
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Ligand-responsive EGFR cancer variants harbor mutations in the kinase domain or point mutations in the extracellular domain. These altered EGFR proteins are able to signal in the absence of ligands, but their ligand binding ability is preserved and downstream signaling is potentiated when ligand is available (Greulich et al. 2005, Lee et al. 2006).

Literature References
PubMed ID Title Journal Year
16187797 Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

Greulich, H, Chen, TH, Feng, WL, Jänne, PA, Alvarez, JV, Zappaterra, M, Bulmer, SE, Frank, DA, Hahn, WC, Sellers, WR, Meyerson, M

PLoS Med 2005
17177598 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain

Lee, JC, Vivanco, I, Beroukhim, R, Huang, JHY, Feng, WL, DeBiasi, RM, Yoshimoto, K, King, JC, Nghiemphu, P, Yuza, Y, Xu, Q, Greulich, H, Thomas, RK, Paez, JG, Peck, TC, Linhart, DJ, Glatt, KA, Getz, G, Onofrio, R, Ziaugra, L, Levine, RL, Gabriel, S, Kawaguchi, T, O'Neill, K, Khan, H, Liau, LM, Nelson, SF, Rao, PN, Mischel, P, Pieper, RO, Cloughesy, T, Leahy, DJ, Sellers, WR, Sawyers, CL, Meyerson, M, Mellinghoff, IK

PLoS Med 2006
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created